J. Mcmichael, J. Lever, G. Burckart, and T. Starzl, Clinical pharmacokinetics of tacrolimus, Clin Pharmacokinet, vol.29, issue.6, pp.404-434, 1995.

M. Kamoun, S. Rosas, K. Mange, B. Strom, K. Brayman et al., Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation, J Am Soc Nephrol, vol.16, issue.6, pp.1839-1887, 2005.

D. Laskow, F. Vincenti, J. Neylan, R. Mendez, and A. Matas, AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATION, Transplantation, vol.62, issue.7, pp.900-905, 1996.
DOI : 10.1097/00007890-199610150-00005

H. Silva, Tacrolimus Once-Daily Formulation in the Prophylaxis of Transplant Rejection in Renal or Liver Allograft Recipients, Drugs, vol.7, issue.6, pp.1944-1949, 2007.
DOI : 10.2165/00003495-200767130-00014

J. Pirsch, A. Matas, J. Zaltzman, K. Wisemandle, W. Fitzsimmons et al., Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients, Transplantation, vol.83, issue.12, pp.1648-51, 2007.

P. Wallemacq, V. Armstrong, M. Brunet, V. Haufroid, D. Holt et al., Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference, Therapeutic Drug Monitoring, vol.31, issue.2, pp.139-52, 2009.
DOI : 10.1097/FTD.0b013e318198d092

S. Wrighton, S. Hall, P. Maurel, M. Relling, C. Brimer et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, vol.27, issue.4, pp.383-91, 2001.

J. Lindemans, W. Weimar, and T. Van-gelder, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clin Pharmacol Ther, vol.74, issue.3, pp.245-54, 2003.

J. Fijter and H. Guchelaar, Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients, Ther Drug Monit Musuamba FT, Mourad M, vol.31, issue.11, pp.187-97, 2009.

P. Marquet and A. Rousseau, Population pharmacokinetics and bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation, Clin Pharmacokinet, vol.49, issue.10, pp.683-92
URL : https://hal.archives-ouvertes.fr/inserm-00926496

C. Staatz, C. Willis, P. Taylor, and S. Tett, Population pharmacokinetics of tacrolimus in adult kidney transplant recipients, Clinical Pharmacology & Therapeutics, vol.72, issue.6, pp.660-669, 2002.
DOI : 10.1067/mcp.2002.129304

M. Antignac, B. Barrou, R. Farinotti, P. Lechat, and S. Urien, Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients, British Journal of Clinical Pharmacology, vol.23, issue.0, pp.750-757, 2007.
DOI : 10.1016/S0041-1345(02)02999-8

F. Villemain, L. Meur, Y. Marquet, P. Rousseau, and A. , Tacrolimus population pharmacokineticpharmacogenetic analysis and Bayesian estimation in renal transplant recipients, Clin Pharmacokinet, vol.48, issue.16, pp.805-821, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01390737

F. Marcoux, J. Debord, N. Undre, A. Rousseau, and P. Marquet, Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies Pharmacokinetic modeling and development of bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation, Clin Pharmacokinet Ther Drug Monit, vol.4432, issue.172, pp.1317-28129, 2005.

A. Boekmann, L. Sheiner, and S. Beal, NONMEM User's Guide -Part V: Introductory Guide.; 1994. 20

B. Frame, R. Miller, and R. Lalonde, Evaluation of Mixture Modeling with Count Data Using NONMEM, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.3, pp.18-69
DOI : 10.1023/A:1025564409649